US-based biotechnology company Ridgeback Biopharmaceuticals has initiated two Phase II clinical trials of EIDD-2801 for the treatment of Covid-19. EIDD-2801 was invented by Drug Innovations at Emory (DRIVE) researchers at Emory University. Ridgeback licensed the programme in March this year.…
Oxford Covid-19 vaccine trials start in South Africa and Brazil
Researchers in South Africa and Brazil have initiated clinical trials to assess a Covid-19 vaccine candidate, ChAdOx1 nCoV-19 (AZD1222), developed by the University of Oxford and licensed to AstraZeneca. Sponsored by Lemann Foundation, the trial in Brazil will assess the…
FibroGen enrols first patient in pamrevlumab’s Covid-19 trial in US
FibroGen has started enrolment for a Phase II clinical trial of pamrevlumab for the treatment of patients hospitalised due to Covid-19 in the US. Pamrevlumab is an antibody designed to block the activity of connective tissue growth factor (CTGF), which…
Few employees want to return to office full-time when lockdowns are eased: Poll
Remote working or working from home has become the new norm during the COVID-19 times which call for maintaining physical distancing and complying with lockdown measures to curb disease spread. Working from home has multiple benefits such as eliminating the…
The UK leads Covid-19 clinical investigations in Europe
As Europe has been significantly impacted by the Covid-19 pandemic, a substantial amount of clinical research is currently focused on identifying effective therapies and vaccines. GlobalData analysed the Covid-19 clinical trials landscape in Europe with a view to identifying key…
Vaxart’s COVID-19 Vaccine Candidate Tapped for Operation Warp Speed Primate Study
One month after Vaxart announced the selection of its lead vaccine candidate for COVID-19, the Bay Area-based company said it has been selected to participate in the U.S. government’s Operation Warp Speed program. The South San Francisco company said this…
Yumanity and Merck Ink $500 Million+ Deal for Neurodegenerative Diseases
Yumanity Therapeutics and Merck signed a strategic research and license deal for two Yumanity programs. The two preclinical programs are for amyotrophic lateral sclerosis (ALS) and frontotemporal lobar dementia (FTLD). Under the terms of the agreement, Merck gains exclusive rights…
FDA Approves Phase III Study of Fulcrum’s Losmapimod in COVID-19
Shares of Fulcrum Therapeutics were up more than 14% in premarket trading after the company announced it will begin the Phase LOSVID III study to assess losmapimod as a potential treatment of COVID-19. This morning Cambridge, Mass.-based Fulcrum said the…
New Data Shows 718 Pipeline Drugs Now Associated with COVID-19
New information released Tuesday by GlobalData showed that there are now more than 718 pipeline drugs associated with COVID-19. In addition, 70% of these products are in the discovery or preclinical stages. “These drugs include combinations of novel agents and…
Clinical Trials Are Starting Back Up, but Some Future Approvals May be Delayed
As the COVID-19 pandemic ramped up in March, April and May around the globe, numerous clinical trials for other diseases were paused in order to free up clinics and hospitals as well as to decrease the risk to patients. If…
